Related Experiment Videos
Oxaliplatin-safety profile: neurotoxicity
1Department of Hematology/Oncology, Martin-Luther University Halle-Wittenberg, Halle, Germany.
Seminars in Oncology
|October 3, 2003
Summary
Oxaliplatin chemotherapy, used for colorectal cancer, can cause reversible neurotoxicity. Strategies exist to manage this side effect, but evidence-based recommendations for prevention are still needed.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Oxaliplatin is crucial in advanced colorectal cancer chemotherapy.
- Its dose-limiting toxicity is cumulative sensory neurotoxicity, which is reversible.
- A unique acute neuropathy, triggered by cold, is also rapidly reversible.
Purpose of the Study:
- To review strategies for preventing and treating oxaliplatin-induced neurotoxicity.
- To discuss the "Stop-and-Go" concept for managing neurotoxicity.
- To highlight potential neuromodulatory agents for neurotoxicity management.
Main Methods:
- Literature review of oxaliplatin-induced neurotoxicity.
- Analysis of the "Stop-and-Go" treatment strategy.
- Evaluation of proposed prophylactic and therapeutic agents.
Main Results:
- Oxaliplatin neurotoxicity is generally reversible, especially with adjuvant therapy.
- Acute cold-induced neuropathy is frequent but transient.
- Several agents show promise for prophylaxis and treatment, but require larger trials.
Conclusions:
- Oxaliplatin neurotoxicity is a manageable, reversible side effect.
- The "Stop-and-Go" concept aids in dose optimization.
- Further research is needed for evidence-based recommendations on neurotoxicity management.